Drug Trial Radar · NCT06073093
A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: Jul 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
264
Actual
Start
Nov 7, 2023
Primary completion
Jun 18, 2025
Study completion Jul 2, 2025
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel group, Phase 2, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose finding study. It is designed to assess efficacy and safety of treatment with SAR441566 for 12 weeks. It will be conducted in male and female adult participants with moderate-to-severe rheumatoid arthritis (RA) not adequately controlled on methotrexate (MTX) and biologic/targeted synthetic disease modifying anti-rheumatic drug (DMARD) naive. Study treatment includes investigational medicinal product (IMP: SAR441566 or placebo) added-on to a background therapy of MTX. Study details include a run-in period (4 to 6 weeks) before randomization to determine eligibility, a treatment period (12 weeks ± 3 days) and a post-treatment period (safety follow-up) (2 weeks ± 3 days). The total number of scheduled study visits will be 8.
Conditions
- Rheumatoid Arthritis
Interventions
SAR441566Drug
Tablet
PlaceboDrug
Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving at least 20% improvement from baseline in the American College of Rheumatology (ACR) score at week 12Time frame: Baseline to Week 12
Locations
102 sites in 19 countries. Site status is shown where the registry gives one.
Amicis Research Center - Northridge - Nordhoff Street- Site Number : 8400023
Northridge, California
Inland Rheumatology & Osteoporosis Medical Group- Site Number : 8400004
Upland, California
UF Health Deerwood Park- Site Number : 8400020
Jacksonville, Florida
Life Clinical Trials- Site Number : 8400028
Margate, Florida
Future Care Solution - Miami- Site Number : 8400019
Miami, Florida
Innovia Research Center, Inc- Site Number : 8400026
Miramar, Florida
Integral Rheumatology and Immunology Specialists- Site Number : 8400010
Plantation, Florida
Clinical Research of West Florida - Tampa - North Howard Avenue- Site Number : 8400017
Tampa, Florida
Inspire Santa Fe Medical Group- Site Number : 8400029
Santa Fe, New Mexico
Arthritis and Osteoporosis Consultants of the Carolinas- Site Number : 8400012
Charlotte, North Carolina
Carolina Specialty Care- Site Number : 8400007
Statesville, North Carolina
Altoona Center for Clinical Research- Site Number : 8400002
Duncansville, Pennsylvania
Low Country Rheumatology- Site Number : 8400018
Summerville, South Carolina
American Indian Clinical Trials Research Network - Rapid City- Site Number : 8400022
Rapid City, South Dakota
Prolato Clinical Research Center- Site Number : 8400021
Houston, Texas
AARA Clinical Research - Lone Star Arthritis & Rheumatology Associates - Irving- Site Number : 8400031
Irving, Texas
Perceptive Pharma Research- Site Number : 8400009
Richmond, Texas
Investigational Site Number : 0320003
Buenos Aires, Argentina
Investigational Site Number : 0320007
Buenos Aires, Argentina
Investigational Site Number : 0320006
Mar del Plata, Argentina
Investigational Site Number : 0320002
San Miguel de Tucumán, Argentina
Investigational Site Number : 0320002
San Miguel de Tucumán, Argentina
Investigational Site Number : 0320005
Berazategui, Buenos Aires, Argentina
Investigational Site Number : 0320004
Buenos Aires, Buenos Aires F.D., Argentina
Investigational Site Number : 0320001
Buenos Aires, Buenos Aires F.D., Argentina
Hospital São Lucas Copacabana- Site Number : 0760007
Rio de Janeiro, Brazil
CCBR / IBPClin - Instituto Brasil de Pesquisa Clínica- Site Number : 0760005
Rio de Janeiro, Brazil
Centro Paulista de Investigaçăo Clínica - CEPIC- Site Number : 0760001
São Paulo, Brazil
Centro Mineiro de Pesquisa- Site Number : 0760003
Juiz de Fora, Minas Gerais, Brazil
Centro de Estudos em Terapias Inovadoras- Site Number : 0760004
Curitiba, Paraná, Brazil
Investigational Site Number : 1240006
Calgary, Alberta, Canada
Investigational Site Number : 1240001
Brampton, Ontario, Canada
Investigational Site Number : 1240004
Windsor, Ontario, Canada
Investigational Site Number : 1240002
Sherbrooke, Quebec, Canada
Investigational Site Number : 1520009
Santiago, Chile
Investigational Site Number : 1520001
La Serena, Coquimbo Region, Chile
Investigational Site Number : 1520003
Osorno, Los Lagos Region, Chile
Investigational Site Number : 1520005
Valdivia, Los Ríos Region, Chile
Investigational Site Number : 1520002
Talca, Maule Region, Chile
Investigational Site Number : 1520004
Santiago, Reg Metropolitana de Santiago, Chile
Showing 40 of 102 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.